Novotech News

1. Novotech Showcased In Global Biotech Series For Innovation In Hepatitis B Research 7/8/2025

   Novotech a globally recognized full-service clinical research organization (CRO) and scientific advisory company, is featured in The Next Frontier, a global branded series presented by the Biotechnology Innovation Organization (BIO) and produced by BBC StoryWorks Commercial Productions.

2. Novotech Welcomes New Investment From GIC, Temasek, And Existing Investor TPG To Accelerate Global Growth 5/14/2025

   Novotech, a globally recognized full-service biotech specialist clinical research organization (CRO), announced today that affiliates of GIC and Temasek have signed binding agreements to acquire a significant stake in the company, with the additional capital earmarked to accelerate its global growth. Existing investor TPG will also reinvest through its TPG Asia fund.

3. Novotech Report Reveals Global Surge In Infectious Disease Trials As Industry Nears 2,000 Studies Since 2020 5/14/2025

   Novotech a globally recognized full-service clinical research organization (CRO) and scientific advisory partner for biotech and small- to mid-sized pharmaceutical companies seeking to advance drug development, has released a new report analyzing the evolving infectious disease clinical trial landscape. This report provides critical strategic insights for pharmaceutical and biotech companies navigating the complexities of global infectious disease research and development in 2025. 

4. Novotech Identifies Strategic Opportunities In Idiopathic Pulmonary Fibrosis Trials With Release Of Global Market Insights 5/14/2025

   Sydney, April 2025 – Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory partner for biotech and small- to mid-sized pharmaceutical companies seeking to advance drug development, has released an in-depth report on the global clinical trial landscape for Idiopathic Pulmonary Fibrosis (IPF). The report offers strategic insights and comprehensive analysis critical for biotech and pharmaceutical companies navigating the complexities of IPF clinical research and drug development. 

5. Novotech Expands South Korean Presence With New Hospital Trial Site Deal 4/4/2025

   Australian CRO Novotech has signed a memorandum of understanding with the Kyungpook National University Hospital (KNUH), furthering its partnership strategy in South Korea.

6. Novotech Named Best Contract Research Organization In Australia At Asia-Pacific Biopharma Excellence Awards 2025 4/3/2025

   Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company that provides biotech and small- to mid-sized pharma companies an accelerated path to market has been recognized as the Best Contract Research Organization in Australia at the Asia-Pacific Biopharma Excellence Awards (ABEA) 2025. 

7. Novotech Report Reveals Growth In siRNA Research 4/3/2025

   Sydney, March 2025 – Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company, has released its newest preclinical report exploring the evolving landscape of small interfering RNA (siRNA) therapeutics. This report provides insights for biotech and pharmaceutical companies leveraging RNA-based precision medicine to develop next-generation treatments for oncology, metabolic disorders, and rare genetic diseases. 

8. Novotech Partners With Kyungpook National University Hospital To Strengthen Clinical Trial Capabilities In South Korea 3/19/2025

   Novotech, a global leading full-service clinical CRO, and Acrostar, a provider of Site Management Organization (SMO) services, have entered into a strategic partnership that will support clinical trials across NHUH’s prestigious institutions including the Advanced Clinical Trials Center, the KNUH main campus, and the Chilgok KNUH in South Korea.

9. Novotech Releases Comprehensive Report On Oncolytic Virus Therapy 1/30/2025

   Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech and small to mid-size pharma companies to accelerate the development of advanced and novel therapeutics, has released its latest report, Oncolytic Virus Therapy: Global Clinical Trial Landscape 2024. This comprehensive whitepaper analyzes the evolving landscape of oncolytic virus therapies (OVT), providing critical insights into this transformative approach to cancer treatment. 

10. Novotech Releases Report On Current State Of Triple-Negative Breast Cancer Clinical Trials 1/30/2025

    Novotech, the leading global full-service clinical Contract Research Organization (CRO), has released a comprehensive report analyzing the global clinical trial and drug development landscape for Triple-Negative Breast Cancer (TNBC). The report highlights significant advancements in therapeutic strategies, regional clinical trial activity, and evolving biomarkers driving innovative TNBC treatments.